A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522951-24-00

Enrollment

Registered

2026-06-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteogenesis Imperfecta

Percent change from Baseline at Month 12 in lumbar spine BMD

DRUGPlacebo to match AGA2115

Sex/Gender

All

Age

18 Years to No maximum

Measure	Time frame
Percent change from Baseline at Month 12 in lumbar spine BMD	—

None listed

Source: EU CTIS · Data processed: Jun 23, 2026